1 |
Rayar M, Tron C, Jézéquel C, et al. High intrapatient variability of tacrolimus exposure in the early period after liver transplantation is associated with poorer outcomes[J]. Transplantation, 2018,102(3):e108-e114.
|
2 |
Ensor CR, Iasella CJ, Harrigan KM, et al. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients[J]. Am J Transplant, 2018,18(6):1527-1533.
|
3 |
Shuker N, Bouamar R, Hesselink DA, et al. Intrapatient variability in tacrolimus exposure does not predict the development of cardiac allograft vasculopathy after heart transplant[J]. Exp Clin Transplant, 2018,16(3):326-332.
|
4 |
Schumacher L, Leino AD, Park JM. Tacrolimus intrapatient variability in solid organ transplantation: a multiorgan perspective[J]. Pharmacotherapy, 2021,41(1):103-118.
|
5 |
Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management[J]. Transplant Rev (Orlando), 2015,29(2):78-84.
|
6 |
Kuypers DRJ. Intrapatient variability of tacrolimus exposure in solid organ transplantation: a novel marker for clinical outcome[J]. Clin Pharmacol Ther, 2020,107(2):347-358.
|
7 |
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation[J]. Clin Pharmacokinet, 2004,43(10):623-653.
|
8 |
Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference[J]. Ther Drug Monit, 2009, 31(2):139-152.
|
9 |
Ekberg H, Bernasconi C, Nöldeke J, et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study[J]. Nephrol Dial Transplant, 2010,25(6):2004-2010.
|
10 |
Bouamar R, Shuker N, Hesselink DA, et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials[J]. Am J Transplant, 2013,13(5):1253-1261.
|
11 |
Shuker N, Shuker L, van Rosmalen J, et al. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation[J]. Transpl Int, 2016,29(11):1158-1167.
|
12 |
Whalen HR, Glen JA, Harkins V, et al. High intrapatient tacrolimus variability is associated with worse outcomes in renal transplantation using a low-dose tacrolimus immunosuppressive regime[J]. Transplantation, 2017,101(2):430-436.
|
13 |
O′Regan JA, Canney M, Connaughton DM, et al. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation[J]. J Nephrol, 2016,29(2):269-276.
|
14 |
Rodrigo E, Segundo DS, Fernández-Fresnedo G, et al. Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development[J]. Transplantation, 2016,100(11):2479-2485.
|
15 |
Cheng EY. The role of humoral alloreactivity in liver transplantation: lessons learned and new perspectives[J]. J Immunol Res, 2017:3234906.
|
16 |
Neuberger JM, Bechstein WO, Kuypers DR, et al. Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) group[J]. Transplantation, 2017,101(4S Suppl 2):S1-S56.
|
17 |
Christina S, Annunziato RA, Schiano TD, et al. Medication level variability index predicts rejection, possibly due to nonadherence, in adult liver transplant recipients[J]. Liver Transpl, 2014,20(10):1168-1177.
|
18 |
Shemesh E, Bucuvalas JC, Anand R, et al. The medication level variability index (MLVI) predicts poor liver transplant outcomes: a prospective multi-site study[J]. Am J Transplant, 2017,17(10):2668-2678.
|
19 |
Pollock-Barziv SM, Finkelstein Y, Manlhiot C, et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children[J]. Pediatr Transplant, 2010,14(8):968-975.
|
20 |
van der Veer MAA, Nangrahary N, Hesselink DA, et al. High intrapatient variability in tacrolimus exposure is not associated with immune-mediated graft injury after liver transplantation[J]. Transplantation, 2019,103(11):2329-2337.
|
21 |
Del Bello A, Congy-Jolivet N, Danjoux M, et al. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation[J]. World J Gastroenterol, 2018,24(16):1795-1802.
|
22 |
Barbier L, Garcia S, Cros J, et al. Assessment of chronic rejection in liver graft recipients receiving immunosuppression with low-dose calcineurin inhibitors[J]. J Hepatol, 2013,59(6):1223-1230.
|
23 |
Terasaki PI. Tolerogenic mechanisms in liver transplantation[J]. SOJ Immunol, 2015, 3(4):1-13.
|
24 |
Merli M, Di Menna S, Giusto M, et al. Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient[J]. Transplant Proc, 2010,42(4):1322-1324.
|
25 |
Quintero J, Juampérez J, Ortega J, et al. Conversion from twice-daily to once-daily tacrolimus formulation in pediatric liver transplant recipients - a long-term prospective study[J]. Transpl Int, 2018,31(1):38-44.
|
26 |
Dumortier J, Duvoux C, Dubel L, et al. A multicenter, prospective, observational study of conversion from twice-daily immediate-release to once-daily prolonged-release tacrolimus in liver transplant recipients in France: the COBALT study[J]. Ann Transplant, 2019,24:506-516.
|
27 |
Knops N, Levtchenko E, van den Heuvel B, et al. From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation[J]. Int J Pharm, 2013,452(1-2):14-35.
|
28 |
Pashaee N, Bouamar R, Hesselink DA, et al. CYP3A5 genotype is not related to the intrapatient variability of tacrolimus clearance[J]. Ther Drug Monit, 2011,33(3):369-371.
|
29 |
Spierings N, Holt DW, MacPhee IA. CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients[J]. Ther Drug Monit, 2013,35(3):328-331.
|
30 |
Ro H, Min SI, Yang J, et al. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation[J]. Ther Drug Monit, 2012,34(6):680-685.
|